| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1027860510 |
| P356 | DOI | 10.1186/1758-5996-1-10 |
| P932 | PMC publication ID | 2761852 |
| P698 | PubMed publication ID | 19825147 |
| P2093 | author name string | Fernando Gerchman | |
| Themis Zelmanovitz | |||
| Luís H Canani | |||
| Amely Ps Balthazar | |||
| Fúlvio Cs Thomazelli | |||
| Jorge D Matos | |||
| P2860 | cites work | Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study | Q22242096 |
| Metformin | Q22250907 | ||
| Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study | Q24652963 | ||
| Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis | Q24655666 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators | Q28144781 | ||
| Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 | ||
| The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes | Q28188182 | ||
| The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE> | Q28204197 | ||
| Smoking is associated with progression of diabetic nephropathy | Q28251046 | ||
| Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group | Q29617736 | ||
| Glucose control and vascular complications in veterans with type 2 diabetes | Q29619213 | ||
| Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group | Q29619460 | ||
| Combination Therapy With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists in the Treatment of Patients With Type 2 Diabetes Mellitus | Q30310845 | ||
| Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes | Q30435965 | ||
| High prevalence of immuno-unreactive intact albumin in urine of diabetic patients | Q30883911 | ||
| Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care | Q31136915 | ||
| Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data | Q31878962 | ||
| Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. | Q33414957 | ||
| Management of drugs affecting blood glucose in diabetic patients with renal failure. | Q33988958 | ||
| The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? | Q34021651 | ||
| Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group | Q34025761 | ||
| Renal and retinal effects of enalapril and losartan in type 1 diabetes | Q34296719 | ||
| Regression of microalbuminuria in type 1 diabetes | Q44467189 | ||
| Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy | Q44544991 | ||
| Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. | Q44546017 | ||
| Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. | Q44563042 | ||
| Nephropathy in diabetes | Q44705106 | ||
| Meta-analysis of small trials: proceed with caution | Q44770237 | ||
| Microalbuminuria is positively associated with usual dietary saturated fat intake and negatively associated with usual dietary protein intake in people with insulin-dependent diabetes mellitus | Q44976361 | ||
| Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans | Q45333759 | ||
| Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials | Q45897743 | ||
| Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). | Q45961602 | ||
| Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design | Q46162422 | ||
| Sources of protein and polyunsaturated fatty acids of the diet and microalbuminuria in type 2 diabetes mellitus. | Q46322973 | ||
| Vascular complications of black patients with type 2 diabetes mellitus in Southern Brazil | Q46363075 | ||
| Long-term effect of a chicken-based diet versus enalapril on albuminuria in type 2 diabetic patients with microalbuminuria. | Q46415344 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). | Q46480414 | ||
| Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis | Q46555031 | ||
| Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 | ||
| Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency | Q46563222 | ||
| Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients | Q46570581 | ||
| Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus | Q46604389 | ||
| Risk factors for micro and macrovascular disease in black and white patients with type 2 diabetes mellitus | Q46618774 | ||
| Evaluation of tests for microalbuminuria screening in patients with diabetes. | Q46655015 | ||
| Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus | Q46696790 | ||
| Reduction of proteinuria by rosiglitazone in non-diabetic renal disease | Q46805468 | ||
| A genome-wide linkage scan for genes controlling variation in urinary albumin excretion in type II diabetes | Q46865476 | ||
| Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus | Q46874844 | ||
| Earlier detection of microalbuminuria in diabetic patients using a new urinary albumin assay | Q47756945 | ||
| Pathogenesis, prevention, and treatment of diabetic nephropathy | Q47770839 | ||
| Reversal of lesions of diabetic nephropathy after pancreas transplantation | Q47879758 | ||
| Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial | Q47978262 | ||
| The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. | Q48552318 | ||
| Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? | Q50657801 | ||
| Withdrawal of red meat from the usual diet reduces albuminuria and improves serum fatty acid profile in type 2 diabetes patients with macroalbuminuria. | Q50735121 | ||
| Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. | Q50859018 | ||
| Urinary albumin excretion rate and glomerular filtration rate in single-kidney type 2 diabetic patients. | Q50867880 | ||
| Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. | Q50888604 | ||
| Determinants of progression of microalbuminuria in patients with NIDDM.A prospective study. | Q50953888 | ||
| Glomerular hyperfiltration in the prediction of nephropathy in IDDM: a 10-year follow-up study. | Q50991798 | ||
| Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. | Q51555685 | ||
| Familial clustering of diabetic nephropathy in Brazilian type 2 diabetic patients. | Q51564414 | ||
| Incidence and determinants of microalbuminuria in Koreans with type 2 diabetes. | Q51570209 | ||
| Nonalbuminuric renal insufficiency in type 2 diabetes. | Q55037977 | ||
| Does bacteriuria interfere with albuminuria measurements of patients with diabetes? | Q58875078 | ||
| Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment | Q60218011 | ||
| Diabetic nephropathy: diagnosis, prevention, and treatment | Q34379284 | ||
| Genetics of diabetic nephropathy: how far are we from finding susceptibility genes? | Q34427224 | ||
| A practical approach to achieving recommended blood pressure goals in diabetic patients | Q34456507 | ||
| Oral antihyperglycemic therapy for type 2 diabetes: scientific review | Q34492673 | ||
| Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor | Q34579106 | ||
| The impact of atherosclerotic renovascular disease on diabetic renal failure | Q34991662 | ||
| Thiazolidinedione use and bone loss in older diabetic adults | Q35023205 | ||
| Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study | Q35107546 | ||
| Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes | Q35161366 | ||
| How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? | Q35209086 | ||
| Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus | Q35822678 | ||
| Which method for quantifying urinary albumin excretion gives what outcome? A comparison of immunonephelometry with HPLC. | Q35918699 | ||
| Effect of renal impairment on the pharmacokinetics of exenatide | Q36024667 | ||
| Evidence for different susceptibility genes for proteinuria and ESRD in type 2 diabetes | Q36094474 | ||
| Detection of urinary albumin | Q36094476 | ||
| From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy | Q36141302 | ||
| Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study | Q36243443 | ||
| Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis | Q36336393 | ||
| Peroxisome proliferator-activated receptor gamma agonists in renal disease | Q36462671 | ||
| Having one kidney does not accelerate the rate of development of diabetic nephropathy lesions in type 1 diabetic patients | Q36819204 | ||
| High-density single nucleotide polymorphism genome-wide linkage scan for susceptibility genes for diabetic nephropathy in type 1 diabetes: discordant sibpair approach | Q36842660 | ||
| Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes | Q36881579 | ||
| Molecular mechanisms of diabetic nephropathy and its therapeutic intervention | Q36907258 | ||
| Standards of medical care in diabetes--2009. | Q37036416 | ||
| Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study | Q37054992 | ||
| Antiproteinuric and anti-inflammatory effects of thiazolidinedione | Q37058538 | ||
| Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). | Q37087865 | ||
| Renal hyperfiltration and the development of microalbuminuria in type 1 diabetes | Q37163742 | ||
| New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy | Q37180781 | ||
| The pathogenesis of diabetic nephropathy | Q37209550 | ||
| New and old markers of progression of diabetic nephropathy | Q37304419 | ||
| Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study | Q37368689 | ||
| Early nephropathy in type 1 diabetes: the importance of early renal function decline | Q37418807 | ||
| Use of thiazolidinediones and fracture risk | Q38456774 | ||
| The changing natural history of nephropathy in type I diabetes | Q38520789 | ||
| The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature | Q38557081 | ||
| National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification | Q39513412 | ||
| Prognostic factors in Brazilian diabetic patients starting dialysis: a 3.6-year follow-up study | Q39554186 | ||
| Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. | Q40382042 | ||
| An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus. | Q40655880 | ||
| Proteinuria: pathophysiology, significance and recommendations for measurement in clinical practice | Q40784981 | ||
| Nephropathy of type-2 diabetes mellitus. | Q40836138 | ||
| The hyperfiltration theory: a paradigm shift in nephrology | Q41066752 | ||
| Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency | Q41149331 | ||
| Familial factors determine the development of diabetic nephropathy in patients with IDDM. | Q41152952 | ||
| Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy | Q41306582 | ||
| Understanding the nature of renal disease progression | Q41314057 | ||
| Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis | Q42602511 | ||
| The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis | Q43490816 | ||
| Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes | Q43511438 | ||
| Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria | Q43590458 | ||
| Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment | Q43647199 | ||
| Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. | Q43808993 | ||
| Glomerular hyperfiltration in NIDDM patients without overt proteinuria | Q43862949 | ||
| Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death | Q43935480 | ||
| Effect of a chicken-based diet on renal function and lipid profile in patients with type 2 diabetes: a randomized crossover trial. | Q43937005 | ||
| Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol | Q43950414 | ||
| Renal outcome in type 2 diabetic patients with or without coexisting nondiabetic nephropathies | Q43972620 | ||
| Advanced glycosylation end products in patients with diabetic nephropathy | Q44031994 | ||
| Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect | Q44090671 | ||
| Polyunsaturated fatty acid consumption may play a role in the onset and regression of microalbuminuria in well-controlled type 1 and type 2 diabetic people: a 7-year, prospective, population-based, observational multicenter study | Q44167681 | ||
| Effectiveness of aldosterone blockade in patients with diabetic nephropathy | Q44269017 | ||
| Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy | Q44288705 | ||
| Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes | Q44295713 | ||
| Rosiglitazone reduces urinary albumin excretion in type II diabetes | Q44305174 | ||
| Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure | Q44317938 | ||
| Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function | Q44333627 | ||
| The effects of weight loss on renal function in patients with severe obesity | Q44449830 | ||
| Smoking and Progression of Diabetic Nephropathy in Type 1 Diabetes | Q61948406 | ||
| Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus | Q68921607 | ||
| Evolution of glomerular filtration rate in proteinuric NIDDM patients | Q70212778 | ||
| Monitoring glomerular function in diabetic nephropathy. A prospective study | Q70425402 | ||
| The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group | Q70513402 | ||
| Predicting diabetic nephropathy in insulin-dependent patients | Q71401816 | ||
| Reference values for 51Cr-EDTA clearance as a measure of glomerular filtration rate | Q71592507 | ||
| Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion | Q71622424 | ||
| Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study | Q71777734 | ||
| Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. Microalbuminuria Collaborative Study Group, United Kingdom | Q71792058 | ||
| Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group | Q71979461 | ||
| Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus | Q72528281 | ||
| Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy | Q72553570 | ||
| The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy | Q72616631 | ||
| Chicken and fish diet reduces glomerular hyperfiltration in IDDM patients | Q72714179 | ||
| Cholesterol: a renal risk factor in diabetic nephropathy? | Q72809751 | ||
| Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients | Q73181271 | ||
| Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions | Q73188443 | ||
| The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy | Q73209687 | ||
| Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study. The Microalbuminuria Collaborative Study Group | Q73250901 | ||
| Promoters of progression of diabetic nephropathy: the relative roles of blood glucose and blood pressure control | Q73622028 | ||
| The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus | Q73733629 | ||
| Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study | Q73829219 | ||
| Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group | Q73842153 | ||
| Higher intakes of fish protein are related to a lower risk of microalbuminuria in young Swedish type 1 diabetic patients | Q73866631 | ||
| Functional and structural changes in the kidney in the early stages of obesity | Q73928010 | ||
| Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate | Q73929141 | ||
| Urinary albumin excretion rate and glomerular filtration rate in the prediction of diabetic nephropathy; a long-term follow-up study of childhood onset type-1 diabetic patients | Q74102050 | ||
| Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: a 9-year follow-up study | Q74181586 | ||
| Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy | Q74351913 | ||
| Genetics of diabetic nephropathy: evidence for major and minor gene effects | Q77317489 | ||
| Renal function and structure in albuminuric type 2 diabetic patients without retinopathy | Q77322429 | ||
| Glomerular filtration rate, urinary albumin excretion rate, and blood pressure changes in normoalbuminuric normotensive type 1 diabetic patients: an 8-year follow-up study | Q78238448 | ||
| Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications | Q78385000 | ||
| Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus: a randomized trial | Q78696026 | ||
| Do patients with type 2 diabetes on peritoneal dialysis need less insulin if they are given rosiglitazone? | Q80166842 | ||
| Renal pathological change in patients with type 2 diabetes is not always diabetic nephropathy: a report of 52 cases | Q80415576 | ||
| Establishing pragmatic estimated GFR thresholds to guide metformin prescribing | Q80729420 | ||
| Urinary albumin excretion rate is associated with increased ambulatory blood pressure in normoalbuminuric type 2 diabetic patients | Q81897800 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | kidney disease | Q1054718 |
| P304 | page(s) | 10 | |
| P577 | publication date | 2009-09-21 | |
| P1433 | published in | Diabetology and Metabolic Syndrome | Q15816649 |
| P1476 | title | Diabetic nephropathy | |
| P478 | volume | 1 |
| Q38788160 | Alcohol Toxicity in Diabetes and Its Complications: A Double Trouble? |
| Q33705531 | Allergic reaction related to ramipril use: a case report |
| Q53371980 | Amelioration of experimentally induced diabetic nephropathy and renal damage by nilotinib. |
| Q41251505 | Antioxidant capacity and structural changes of human serum albumin from patients in advanced stages of diabetic nephropathy and the effect of the dialysis. |
| Q42883148 | Apo E gene polymorphism affects development of type 2 diabetic nephropathy in Asian populations, especially in East Asians: an updated meta-analysis |
| Q38883206 | Apolipoprotein E genotyping in Egyptian diabetic nephropathy patients |
| Q34075371 | Appropriateness of the Zucker Diabetic Fatty rat as a model for diabetic microvascular late complications |
| Q35494290 | Assessment of vascular function in individuals with hyperglycemia: a cross-sectional study of glucose - induced changes in digital volume pulse |
| Q37102552 | Association of APOA5 Gene Promoter Region -1131T>C Polymorphism (rs662799) to Plasma Triglyceride Level in Patients with Type 2 Diabetic Nephropathy |
| Q37266699 | Association of Salivary Osteopontin Levels with Glycaemic Status and Microalbuminuria - in Patients with Type 2 Diabetes Mellitus |
| Q49267983 | Beneficial Effect of Bis(Hinokitiolato)Zn Complex on High-fat Diet-induced Lipid Accumulation in Mouse Liver and Kidney |
| Q33587783 | Challenges in achieving optimal glycemic control in type 2 diabetes patients with declining renal function: The Southeast Asia perspective |
| Q37235023 | Characterization of the development of renal injury in Type-1 diabetic Dahl salt-sensitive rats |
| Q38609767 | Chinese medicines in the treatment of experimental diabetic nephropathy. |
| Q37368852 | Comparison of the Development Diabetic Induced Renal Disease in Strains of Goto-Kakizaki Rats |
| Q36816626 | Comparison of urinary protein: creatinine index and dipsticks for detection of microproteinuria in diabetes mellitus patients |
| Q35544870 | Correlation of spot urine protein-creatinine ratio with 24-hour urinary protein in type 2 diabetes mellitus patients: A cross sectional study |
| Q41366870 | Diabetic glomerulosclerosis can be the pathogenesis of refractory diabetic macular edema |
| Q38130262 | Diabetic nephropathy: Treatment with phosphodiesterase type 5 inhibitors |
| Q26769787 | Drug Targets for Oxidative Podocyte Injury in Diabetic Nephropathy |
| Q37055066 | Effect of angiotensin converting enzyme inhibitor on glomerular hyperfiltration in patients with type 1 diabetes |
| Q85651017 | Effect of mononuclear cells versus pioglitazone on streptozotocin-induced diabetic nephropathy in rats |
| Q34500566 | Environmental tobacco smoke furthers progression of diabetic nephropathy |
| Q50859753 | Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse. |
| Q51759559 | Fenofibrate attenuates diabetic nephropathy in experimental diabetic rat's model via suppression of augmented TGF-β1/Smad3 signaling pathway. |
| Q34434682 | Fluctuation between fasting and 2-H postload glucose state is associated with glomerular hyperfiltration in newly diagnosed diabetes patients with HbA1c < 7%. |
| Q64073002 | Genetic associations between genes in the renin-angiotensin-aldosterone system and renal disease: a systematic review and meta-analysis |
| Q33953983 | Homocysteine and Hypertension in Diabetes: Does PPARgamma Have a Regulatory Role? |
| Q51869814 | Induction of hyperglycemia in adult intrauterine growth-restricted rats: effects on renal function. |
| Q91671449 | Interaction between ELMO1 gene polymorphisms and environment factors on susceptibility to diabetic nephropathy in Chinese Han population |
| Q40511135 | Kidney Injury Molecule Levels in Type 2 Diabetes Mellitus. |
| Q28543063 | Mangiferin attenuates diabetic nephropathy by inhibiting oxidative stress mediated signaling cascade, TNFα related and mitochondrial dependent apoptotic pathways in streptozotocin-induced diabetic rats |
| Q89519397 | MicroRNA-21 as an Early Marker of Nephropathy in Patients with Type 1 Diabetes |
| Q36112535 | Microvascular Complications and Their Associated Risk Factors in Newly Diagnosed Type 2 Diabetes Mellitus Patients |
| Q38248725 | Nitric oxide in the normal kidney and in patients with diabetic nephropathy |
| Q38187444 | Nitric oxide system and diabetic nephropathy |
| Q37670559 | Nondiabetic Renal Disease in type 2 Diabetes Mellitus Patients: A Clinicopathological Study |
| Q54935923 | Osteomeles schwerinae Extract Prevents Diabetes-Induced Renal Injury in Spontaneously Diabetic Torii Rats. |
| Q35719805 | Polymorphisms of the UCP2 Gene Are Associated with Glomerular Filtration Rate in Type 2 Diabetic Patients and with Decreased UCP2 Gene Expression in Human Kidney. |
| Q37636866 | Prevalence of and Factors Associated with Nephropathy in Diabetic Patients Attending an Outpatient Clinic in Harare, Zimbabwe |
| Q36707919 | Protective Effects of Curcumin on Renal Oxidative Stress and Lipid Metabolism in a Rat Model of Type 2 Diabetic Nephropathy |
| Q38217707 | Research progress in signalling pathway in diabetic nephropathy |
| Q36127846 | The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country |
| Q26772301 | The role of progranulin in diabetes and kidney disease |
| Q41890464 | Tinospora cordifolia consumption ameliorates changes in kidney chondroitin sulphate/dermatan sulphate in diabetic rats |
Search more.